Search company, investor...

Founded Year

2017

Stage

Debt - II | Alive

Total Raised

$4.09M

Last Raised

$830K | 7 mos ago

About Ricovr Healthcare

RICOVR Healthcare is the creator of the XALIVA rapid diagnostics platform that provides high-quality, rapid diagnostics results using a small amount of saliva. The company’s product pipeline includes rapid point-of-care tests for Covid-19, THC & drugs-of-abuse, and infectious diseases. The company's patented biosensor platform uses a small drop of saliva to provide high-quality, cost-effective results in approximately five minutes, enabling employers, healthcare systems, and law enforcement to carry out cost-effective, non- invasive workplace and roadside testing. Ricovr Healthcare was founded in 2017 and is based in Princeton, New Jersey.

Headquarters Location

303A College Rd E

Princeton, New Jersey, 08540,

United States

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Ricovr Healthcare's Products & Differentiators

    Xaliva THC

    Point-of-need oral fluid test for detection of recent cannabis use

You're one click away from the most comprehensive, unmatched analyst expertise in tech, in-depth private company data and a platform that brings it all together.
Click Now. Join a live demo
Join a demo

Expert Collections containing Ricovr Healthcare

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ricovr Healthcare is included in 1 Expert Collection, including Digital Health.

D

Digital Health

10,563 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Ricovr Healthcare Patents

Ricovr Healthcare has filed 2 patents.

The 3 most popular patent topics include:

  • Betacoronaviruses
  • Coronaviridae
  • Cytokines
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/16/2020

Fiber optics, Spectroscopy, Optical fiber, Microwave technology, Telecommunications equipment

Application

Application Date

11/16/2020

Grant Date

Title

Related Topics

Fiber optics, Spectroscopy, Optical fiber, Microwave technology, Telecommunications equipment

Status

Application

Latest Ricovr Healthcare News

Jo McGuire, Renowned Expert in the Drug Testing Industry, Joins Ricovr Healthcare as Advisor

Aug 15, 2023

News Provided By Share This Article Jo McGuire Joins Ricovr: Pioneering the Future of Drug-Free Workplaces Joining Ricovr is both an honor and a testament to the shared commitment we have towards ensuring safer, drug-free work environments.” — Jo McGuire PRINCETON, NJ, UNITED STATES, August 15, 2023/ EINPresswire.com / -- Ricovr is pleased to announce the appointment of Jo McGuire as a strategic advisor to the company. Jo's reputation is marked by her unwavering dedication to fostering safe work environments, free from the influence of drugs and alcohol. She is a renowned expert in creating policies and identifying tools for creating drug-free workplaces. With a legacy spanning over a decade in the drug and alcohol testing industry, Jo brings unparalleled expertise and insights to the Ricovr team. Her remarkable journey includes steering NDASA (National Drug and Alcohol Screening Association) as its Executive Director, where she masterfully manages the day-to-day operations and drives the association's vision under the watchful eyes of its Board of Directors and committees. Commenting on the appointment, Ricovr's CEO Himanshu Bhatia, stated, "We are elated to have Jo onboard. Her profound expertise aligns perfectly with Ricovr's ethos. With Jo's guidance, we aim to further our commitment to ensuring safer, drug-free workplaces for our clients and their employees." "Joining Ricovr is both an honor and a testament to the shared commitment we have towards ensuring safer, drug-free work environments. Together, I am confident that we will champion a future where workplaces are not just drug-free, but also supportive and empowering for everyone." said Jo McGuire. As a fervent advocate for drug-free workplaces, families, and communities, Jo has earned national respect. Her notable achievements include her appointed role in the Taxation, Banking & Civil Law work-group for the Governor’s Task Force in Colorado to regulate Amendment 64. This assignment leveraged her profound understanding of workplace drug and alcohol testing. Moreover, on the global stage, Jo represented the industry during the United Nations General Assembly on World Drug Agreements, underscoring her prominence in the field. Apart from her strategic roles, Jo's voice resonates in the corridors of national conferences where she is a sought-after speaker. Her prowess as a writer and public policy advisor, paired with her impactful engagements, has established her as a subject matter expert par excellence. As Ricovr continues to surge forward in its mission, the addition of Jo as a strategic advisor marks a significant milestone in the company’s journey towards creating a more responsible and safer work environment across industries. For media inquiries, please contact Himanshu Bhatia

Ricovr Healthcare Frequently Asked Questions (FAQ)

  • When was Ricovr Healthcare founded?

    Ricovr Healthcare was founded in 2017.

  • Where is Ricovr Healthcare's headquarters?

    Ricovr Healthcare's headquarters is located at 303A College Rd E, Princeton.

  • What is Ricovr Healthcare's latest funding round?

    Ricovr Healthcare's latest funding round is Debt - II.

  • How much did Ricovr Healthcare raise?

    Ricovr Healthcare raised a total of $4.09M.

  • Who are the investors of Ricovr Healthcare?

    Investors of Ricovr Healthcare include Halley Venture Partners and Floret Ventures.

  • Who are Ricovr Healthcare's competitors?

    Competitors of Ricovr Healthcare include Hound Labs and 2 more.

  • What products does Ricovr Healthcare offer?

    Ricovr Healthcare's products include Xaliva THC and 2 more.

CB Insights
Looking for a leg up on competitive, customer and technology insights?
CB Insights puts confidence and clarity into your most strategic decisions.
See how. Join a demo.
Join a demo
Trusted by the world's smartest companies to:
  • Predict emerging trends
  • See competitors' playbooks
  • Stalk the smart money
  • Identify tomorrow's challengers
  • Spot growing industries
  • Kill analyst data work
Let's see how we can help you!
MicrosoftWalmartWells Fargo

Compare Ricovr Healthcare to Competitors

O
Omega Optics

Omega Optics is a company that received a SBIR Phase I grant for a project entitled: Photonic Crystal Slot Waveguide Miniature Spectrometer for In-Situ Groundwater Contaminant and Greenhouse Gas Detection and Identification. Their project will develop a 100 micron long lab-on-a-chip spectrometer to detect benzene, toluene, ethylbenzene, and xylenes (BTEX) and other compounds in contaminated ground water and methane and nitrous oxides in air emissions. The project will develop a photonic crystal slot waveguide device which will combine slow light effect in photonic crystal waveguides with large optical field intensity in a low index slot at the center of the photonic crystal waveguide. This will allow exact identification of analyte through spectroscopic signatures. The broader/commercial impact of the project will be realized with the successful demonstration of this technology that will permit this chip to be adapted to a wide range of contaminants in water and air media, and hence, could be very useful to activities in the environmental field. Omega Optics is a company that received a STTR Phase II grant for a project entitled: Fully Embedded Optical Interconnects based on Optical Bus Architecture for Large Size Printed Circuit Boards. Their research project is to develop a commercial board level optical interconnect using bus architecture. Conventional copper links on printed circuit boards fail to provide sufficient bandwidth for data transfer above 10 Gbit/sec. Optical interconnections are widely viewed as an alternative to higher throughput. However, existing photonics-related approaches suffer from issues of packaging, reliability and manufacturing cost. In this project, Omega Optics and the University of Texas at Austin seek to develop a fully embedded board level optical interconnect for enhanced bandwidth, while reducing the difficulties of optoelectronic packaging and device reliability. Phase I results demonstrated 150 GHz bandwidth with 51 cm interconnection distance. Instead of utilizing surface mounted optical components this approach separates the fabrication of the optical layer with the electrical parts and laminates it inside printed circuit boards, between which the interconnection is setup through in-layer vias. This fully embedded technology seals all the optical components and provides a seamless interface with electrical layers, therefore it eliminates the concerns of external optoelectronic devices for end users. The revolutionary breakthrough over copper links sought through this research would benefit the entire computer industry and enable the continued progression of bandwidth and interconnect distance. Omega Optics is a company that received a STTR Phase I grant for a project entitled: Electrically pumped silicon laser for monolithic integration of electronics and photonics. Their research project aims at developing a practical silicon laser with the ultimate goal of monolithic integration of electronics and photonics on a single silicon substrate. Past approaches to silicon light sources, including Si/Ge superlattices, porous silicon, silicon nanocrystals, a variety of silicon-rich oxide structures, bulk silicon with a textured surface, and various optical pumping schemes have made noteworthy progress through the last few decades. Nonetheless, an electrically pumped silicon laser with satisfactory quantum efficiency has yet to be demonstrated. The proposed program exploits a recent development based on doped silicon nanostructures formed from mixtures of spin-on-dopant and spin-on-glass, which has already achieved an external quantum efficiency of 0.013% and obvious linewidth narrowing above a clear threshold, all at room temperature. The prior development, however, suffered from a poor waveguide structure which collected generated photons inefficiently and lowered effective gain. This project will attempt to solve this problem by investigating the spatial gain profile and designing a waveguide structure tailored to maximize the overlap of the optical mode field of the waveguide and the spatial gain profile. The proposed program aims at enhancing the external quantum efficiency to a few percent, which becomes comparable to compound semiconductor lasers. Having electronics and optics work together on one silicon chip has been the vision of generations of scientists and engineers. Developing an electrically pumped silicon laser is a crucial step toward realizing this vision. Yet the intrinsically weak photon emission capability made the use of silicon problematic. A silicon laser would enable the integration of all optoelectronic components on a single silicon chip. Such chips may find applications in computers, consumer electronics, and medical devices. A special feature of the proposed silicon laser approach is its simple fabrication process, which is readily compatible with modern silicon VLSI technology. This would hasten adoption of the technology into the marketplace. Omega Optics is a company that received a STTR Phase I grant for a project entitled: Fully Embedded Optical Interconnect Layers Based on Molded Polymer Lightwave Components for Large Field Size Printed Circuit Boards. Their project aims at developing a commercially viable optical interconnect technology. Conventional optical interconnect technologies suffer from planar optical waveguides with small dimensions in the vertical direction, which leads to alignment difficulties, laser coupling efficiency reduction, and deteriorated packaging reliability. These optical interconnect technologies also fail to provide transmission over a large field size, and the insertion of optical interconnects is incompatible with electronic device packaging. In this program, it is proposed to develop a fully embedded optical interconnection layer within the three dimensional (3D) electrical interconnect layers using molded optical waveguides in conjunction with thin film lasers and thin film photodetectors (both ~ 10 micron in thickness). The selection of polymer based molded waveguides solves two pending problems, the small field size of the interconnects and the shallow depth of the waveguides. The proposers intend to demonstrate up to 24"x36" molded waveguide films having waveguide dimensions of 50 microns by 50 microns, which make the alignment, and therefore packaging, of laser diodes and photodetectors highly reliable. Such a waveguide depth is not economically feasible using any other waveguide technologies. Commercially, using current communication devices, future data transmission demands at the printed circuit board and system level will be difficult to achieve with current copper interconnect technology due to issues regarding signal attenuation, electromagnetic interference, and parasitic noise. The state of the art electrical interconnect technology is anticipated to hit a deadlock between 2008 and 2012 at speeds above 10Gb/s. The proposed research provides a unique solution that reliably incorporates the optical interconnects into printed circuit board (PCB) fabrication and integration. The result of this research program will lay a solid foundation for a future PCB industry, which is critical for the United States to lead the market for the years to come.

Pkvitality Logo
Pkvitality

PKvitality is a bio-wearable company that designs self-monitoring solutions for diabetes. The K'Watch is a CGM (Continuous Glucose Monitor) device that tracks glucose levels continuously throughout the day and night. The company was founded in 2017 and is based in Paris, France.

Baebies Logo
Baebies

Baebies developed a nimble bioassay automation platform to rapidly perform multiplex enzymatic assays and other tests. The company licensed its core technology, digital microfluidics, from Illumina. In addition to a technology license in newborn screening that does not include sequencing, Baebies also received equipment, contracts, and other consideration in exchange for a share of ownership in the new company. The company was founded in 2013 and is based in Durham, North Carolina.

S
Safetest Comercio de Diagnostico

Safetest Comercio de Diagnostico produces diagnostic kits for detection of diseases in animals and humans from the isolation of specific antigens.

N
NanoSpot.ai

NanoSpot.ai is a diagnostic company that delivers artificial intelligence-based diagnoses to the point of care. It uses a protein system and artificial intelligence to deliver data at the point of care. The company was founded in 2021 and is based in Salt Lake City, Utah.

S
Senzo

Senzo develops deep-technology biomedical testing products. It offers COVID-19 test products based on amplified lateral flow (ALF) technology and also integrates with flu testing, tuberculosis, human immunodeficiency virus (HIV), and hepatitis testing. It caters to the clinical testing industry. The company was founded in 2019 and is based in London, United Kingdom.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.